Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

161. Home-based telerehabilitation is not inferior to a centre-based program in patients with chronic heart failure: a randomised trial

Home-based telerehabilitation is not inferior to a centre-based program in patients with chronic heart failure: a randomised trial 28336297 2017 03 24 2017 04 23 1836-9561 63 2 2017 Apr Journal of physiotherapy J Physiother Home-based telerehabilitation is not inferior to a centre-based program in patients with chronic heart failure: a randomised trial. 101-107 S1836-9553(17)30031-0 10.1016/j.jphys.2017.02.017 Is a 12-week, home-based telerehabilitation program conducted in small groups non (...) -inferior to a traditional centre-based program in terms of the change in 6-minute walk distance? Is the telerehabilitation program also non-inferior to a centre-based program in terms of functional capacity, muscle strength, quality of life, urinary incontinence, patient satisfaction, attendance rates, and adverse events? Randomised, parallel, non-inferiority trial with concealed allocation, intention-to-treat analysis and assessor blinding. Patients with stable chronic heart failure (including heart failure

EvidenceUpdates2017

162. Heart failure.

Heart failure. Heart failure is common in adults, accounting for substantial morbidity and mortality worldwide. Its prevalence is increasing because of ageing of the population and improved treatment of acute cardiovascular events, despite the efficacy of many therapies for patients with heart failure with reduced ejection fraction, such as angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), β blockers, and mineralocorticoid receptor antagonists, and advanced (...) device therapies. Combined angiotensin receptor blocker neprilysin inhibitors (ARNIs) have been associated with improvements in hospital admissions and mortality from heart failure compared with enalapril, and guidelines now recommend substitution of ACE inhibitors or ARBs with ARNIs in appropriate patients. Improved safety of left ventricular assist devices means that these are becoming more commonly used in patients with severe symptoms. Antidiabetic therapies might further improve outcomes

Lancet2017

163. Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure.

Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. Background In patients with acute heart failure, early intervention with an intravenous vasodilator has been proposed as a therapeutic goal to reduce cardiac-wall stress and, potentially, myocardial injury, thereby favorably affecting patients' long-term prognosis. Methods In this double-blind trial, we randomly assigned 2157 patients with acute heart failure to receive a continuous intravenous infusion of either ularitide (...) % of patients with paired data. Conclusions In patients with acute heart failure, ularitide exerted favorable physiological effects (without affecting cardiac troponin levels), but short-term treatment did not affect a clinical composite end point or reduce long-term cardiovascular mortality. (Funded by Cardiorentis; TRUE-AHF ClinicalTrials.gov number, NCT01661634 .).

NEJM2017

164. Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure: The CAT-HF Trial

Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure: The CAT-HF Trial 28335841 2017 03 24 2017 03 24 1558-3597 69 12 2017 Mar 28 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure: The CAT-HF Trial. 1577-1587 S0735-1097(17)30439-4 10.1016/j.jacc.2017.01.041 Sleep apnea is common in hospitalized heart failure (HF (...) ) patients and is associated with increased morbidity and mortality. The CAT-HF (Cardiovascular Improvements With MV-ASV Therapy in Heart Failure) trial investigated whether minute ventilation (MV) adaptive servo-ventilation (ASV) improved cardiovascular outcomes in hospitalized HF patients with moderate-to-severe sleep apnea. Eligible patients hospitalized with HF and moderate-to-severe sleep apnea were randomized to ASV plus optimized medical therapy (OMT) or OMT alone (control). The primary endpoint

EvidenceUpdates2017

165. Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload

Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload 28302292 2017 03 17 2017 03 17 1558-3597 69 11 2017 Mar 21 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload. 1409-1419 S0735-1097(17)30278-4 10.1016/j.jacc.2016.12.035 In patients with acute heart failure (AHF), dyspnea relief is the most immediate goal. Renal dysfunction, diuretic resistance (...) differences in dyspnea warrant further exploration of the temporal relationship between diuresis and dyspnea relief and a possible clinical role for tolvaptan. (Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management [SECRET of CHF]; NCT01584557). Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. Konstam Marvin A MA

EvidenceUpdates2017

166. Association Between Rheumatoid Arthritis and Risk of Ischemic and Nonischemic Heart Failure

Association Between Rheumatoid Arthritis and Risk of Ischemic and Nonischemic Heart Failure 28279294 2017 03 10 2017 03 10 1558-3597 69 10 2017 Mar 14 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Association Between Rheumatoid Arthritis and Risk of Ischemic and Nonischemic Heart Failure. 1275-1285 S0735-1097(17)30196-1 10.1016/j.jacc.2016.12.033 It is unknown whether the increased risk of heart failure (HF) in rheumatoid arthritis (RA) is independent of ischemic heart (...) disease (IHD). This study sought to investigate the relative risk of HF overall and by subtype (ischemic and nonischemic HF) in patients with RA and to assess the impact of RA disease factors. Two contemporary cohorts of RA subjects were identified from Swedish patient and rheumatology registries and matched 1:10 to general population comparator subjects. A first-ever HF diagnosis (classified as ischemic HF or nonischemic HF based on the presence of IHD) was assessed through registry linkages. Relative

EvidenceUpdates2017

167. The effect of exercise training on biventricular myocardial strain in heart failure with preserved ejection fraction

The effect of exercise training on biventricular myocardial strain in heart failure with preserved ejection fraction 28772048 2018 11 13 2055-5822 4 3 2017 Aug ESC heart failure ESC Heart Fail The effect of exercise training on biventricular myocardial strain in heart failure with preserved ejection fraction. 356-359 10.1002/ehf2.12149 High-intensity interval training (HIIT) improves peak oxygen uptake and left ventricular diastology in patients with heart failure with preserved ejection (...) , respectively). In patients with HFpEF, 4 weeks of HIIT significantly improved RV-GLS. © 2017 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. Angadi Siddhartha S SS http://orcid.org/0000-0002-2932-7926 School of Nutrition and Health Promotion, Arizona State University, Phoenix, AZ, USA. Department of Cardiovascular Diseases, Mayo Clinic Arizona, Scottsdale, AZ, USA. Jarrett Catherine L CL School of Nutrition and Health Promotion, Arizona

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

168. Metabolic profiles in heart failure due to non‐ischemic cardiomyopathy at rest and under exercise

Metabolic profiles in heart failure due to non‐ischemic cardiomyopathy at rest and under exercise 28451455 2018 11 13 2055-5822 4 2 2017 May ESC heart failure ESC Heart Fail Metabolic profiles in heart failure due to non-ischemic cardiomyopathy at rest and under exercise. 178-189 10.1002/ehf2.12133 Identification of metabolic signatures in heart failure (HF) patients and evaluation of their diagnostic potential to discriminate HF patients from healthy controls during baseline and exercise (...) conditions. Plasma samples were collected from 22 male HF patients with non-ischemic idiopathic cardiomyopathy and left ventricular systolic dysfunction and 19 healthy controls before (t0), at peak (t1) and 1 h after (t2) symptom-limited cardiopulmonary exercise testing. Two hundred fifty-two metabolites were quantified by gas chromatography-mass spectrometry (GC-MS) and liquid chromatography (LC)-MS/MS-based metabolite profiling. Plasma metabolite profiles clearly differed between HF patients and

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

169. Differentiating heart failure phenotypes using sex‐specific transcriptomic and proteomic biomarker panels

Differentiating heart failure phenotypes using sex‐specific transcriptomic and proteomic biomarker panels 28772032 2018 11 13 2055-5822 4 3 2017 Aug ESC heart failure ESC Heart Fail Differentiating heart failure phenotypes using sex-specific transcriptomic and proteomic biomarker panels. 301-311 10.1002/ehf2.12136 Heart failure with preserved ejection fraction (HFpEF) accounts for 30-50% of patients with heart failure (HF). A major obstacle in HF management is the difficulty (...) in differentiating between HFpEF and heart failure with reduced ejection fraction (HFrEF) using conventional clinical and laboratory investigations. The aim of this study is to develop robust transcriptomic and proteomic biomarker signatures that can differentiate HFpEF from HFrEF. A total of 210 HF patients were recruited in participating institutions from the Alberta HEART study. An expert clinical adjudicating panel differentiated between patients with HFpEF and HFrEF. The discovery cohort consisted of 61

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

171. Periodontitis and bone metabolism in patients with advanced heart failure and after heart transplantation

Periodontitis and bone metabolism in patients with advanced heart failure and after heart transplantation 28451454 2018 11 13 2055-5822 4 2 2017 May ESC heart failure ESC Heart Fail Periodontitis and bone metabolism in patients with advanced heart failure and after heart transplantation. 169-177 10.1002/ehf2.12126 Heart failure (HF) is a multi-organ, pro-inflammatory syndrome that impairs bone metabolism. Pro-inflammatory cytokines and bone catabolism enhance periodontal disease, a local (...) inflammatory, bacteria-induced disease that causes bone loss and periodontal soft tissue destruction. Medical and dental examinations were performed on patients with HF ( n = 39), following heart transplantation (post-HTx, n = 38) and controls ( n = 32). Blood, saliva, and gingival crevicular fluid were analysed for bone metabolism and inflammation markers. HF average New York Heart Association classification was III. Average time since HTx was 1414 days. Pro-inflammatory tumour necrosis factor-alpha

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

172. Abnormal haemodynamic postural response in patients with chronic heart failure

Abnormal haemodynamic postural response in patients with chronic heart failure 28451451 2018 11 13 2055-5822 4 2 2017 May ESC heart failure ESC Heart Fail Abnormal haemodynamic postural response in patients with chronic heart failure. 146-153 10.1002/ehf2.12127 The objective was to evaluate in treated heart failure (HF) patients whether multidrug therapy interferes with the cardiovascular autonomic response to postural stress. Blood pressure (BP; Finapres), heart rate (HR), stroke volume (...) , and total peripheral resistance (TPR) responses to standing up were measured in 33 HF patients and 10 healthy age-matched controls. Ten hypertensive (HT) patients treated with a similar combination of drugs but without heart failure served as reference subjects to account for use of medication. Frequency domain measures of HR and BP variability were calculated as correlates of cardiovascular autonomic function. Postural hypotension was found in 16 out of 33 HF patients independently from New York Heart

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

173. Worse prognosis of real-world patients with acute heart failure from the Czech AHEAD registry in comparison to patients from the RELAX-AHF trial.

Worse prognosis of real-world patients with acute heart failure from the Czech AHEAD registry in comparison to patients from the RELAX-AHF trial. 28217307 2017 02 20 2017 02 26 4 1 2017 Feb ESC heart failure ESC Heart Fail Worse prognosis of real-world patients with acute heart failure from the Czech AHEAD registry in comparison to patients from the RELAX-AHF trial. 8-15 10.1002/ehf2.12105 The randomized clinical trial RELAX-AHF demonstrated a positive effect of vasodilator therapy (...) Eur J Heart Fail. 2008 Dec;10(12):1215-23 19006680 Am Heart J. 2014 Apr;167(4):529-36 24655702 Clin Res Cardiol. 2015 Oct;104(10):850-60 25903109 Eur J Heart Fail. 2015 Feb;17(2):224-32 25678098 Intensive Care Med. 2011 Feb;37(2):290-301 21086112 J Am Coll Cardiol. 2008 Jul 29;52(5):347-56 18652942 J Am Coll Cardiol. 2000 Sep;36(3):832-7 10987607 AHEAD registry Acute heart failure Blood pressure Mortality Vasodilator therapy 2016 03 17 2016 06 09 2016 06 21 2017 2 21 6 0 2017 2 22 6 0 2017 2 22 6

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

174. Ghrelin and hormonal markers under exercise training in patients with heart failure with preserved ejection fraction: results from the Ex-DHF pilot study.

Ghrelin and hormonal markers under exercise training in patients with heart failure with preserved ejection fraction: results from the Ex-DHF pilot study. 28217313 2017 02 20 2017 02 26 4 1 2017 Feb ESC heart failure ESC Heart Fail Ghrelin and hormonal markers under exercise training in patients with heart failure with preserved ejection fraction: results from the Ex-DHF pilot study. 56-65 10.1002/ehf2.12109 Over 50% of patients with symptomatic heart failure (HF) experience HF with preserved (...) Feb 27;309(8):781-91 23443441 N Engl J Med. 2006 Jul 20;355(3):251-9 16855265 J Gerontol A Biol Sci Med Sci. 2014 Jun;69(6):675-81 24013674 Biomarkers Exercise Ghrelin Heart failure Training 2016 02 18 2016 07 06 2016 07 19 2017 2 21 6 0 2017 2 22 6 0 2017 2 22 6 0 ppublish 28217313 10.1002/ehf2.12109 EHF212109 PMC5292632

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

175. On admission serum sodium and uric acid levels predict 30 day rehospitalization or death in patients with acute decompensated heart failure

On admission serum sodium and uric acid levels predict 30 day rehospitalization or death in patients with acute decompensated heart failure 28451453 2018 11 13 2055-5822 4 2 2017 May ESC heart failure ESC Heart Fail On admission serum sodium and uric acid levels predict 30 day rehospitalization or death in patients with acute decompensated heart failure. 162-168 10.1002/ehf2.12135 A considerable proportion of hospitalized patients for acute decompensated heart failure will be readmitted or die (...) in short-term follow-up. In the present study, we aimed to assess the role of admission sodium (Na) and uric acid (UA) levels in the prediction of 30 day post-discharge heart failure readmission or all-cause mortality in advanced heart failure patients admitted with acute decompensation. One hundred and forty consecutive advanced heart failure patients who were admitted for a recent cardiac decompensation were enrolled in this prospective study. Serum Na and UA levels remained statistically unchanged

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

176. Kyoto Congestive Heart Failure (KCHF) study: rationale and design

Kyoto Congestive Heart Failure (KCHF) study: rationale and design 28772047 2018 11 13 2055-5822 4 3 2017 Aug ESC heart failure ESC Heart Fail Kyoto Congestive Heart Failure (KCHF) study: rationale and design. 216-223 10.1002/ehf2.12138 Over the last decade, major developments in medicine have led to significant changes in the clinical management of heart failure patients. This study was designed to evaluate the recent trends in clinical characteristics, management, and short-term and long-term (...) prognosis of patients with acute decompensated heart failure (ADHF) in Japan. The Kyoto Congestive Heart Failure study is a prospective, observational, multicentre cohort study, enrolling consecutive ADHF patients from 19 participating hospitals in Japan from November 2014 to March 2016. A total of 4000 patients will be enrolled into the study and patients' anthropometric, socio-economic, and clinical data from hospital admission to discharge will be collected. In addition, in a pre-determined subgroup

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

177. Value of Cardiovascular Magnetic Resonance Imaging–Derived Baseline Left Ventricular Ejection Fraction and Volumes for Precise Risk Stratification of Patients With Ischemic Cardiomyopathy: Insights From the Surgical Treatment for Ischemic Heart Failure

Value of Cardiovascular Magnetic Resonance Imaging–Derived Baseline Left Ventricular Ejection Fraction and Volumes for Precise Risk Stratification of Patients With Ischemic Cardiomyopathy: Insights From the Surgical Treatment for Ischemic Heart Failure 28199489 2018 11 13 2380-6591 2 5 2017 May 01 JAMA cardiology JAMA Cardiol Value of Cardiovascular Magnetic Resonance Imaging-Derived Baseline Left Ventricular Ejection Fraction and Volumes for Precise Risk Stratification of Patients (...) With Ischemic Cardiomyopathy: Insights From the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. 577-579 10.1001/jamacardio.2016.5492 Pai Ramdas G RG Department of Medicine/Cardiology, University of California, Riverside School of Medicine, Riverside. Varadarajan Padmini P Department of Medicine/Cardiology, Loma Linda University, Loma Linda, California. Rouleau Jean L JL Department of Medicine/Cardiology, Montréal Heart Institute, Université de Montréal, Montréal, Quebec, Canada. Stebbins Amanda

JAMA cardiology2017 Full Text: Link to full Text with Trip Pro

178. Risk of heart failure after community acquired pneumonia: prospective controlled study with 10 years of follow-up.

Risk of heart failure after community acquired pneumonia: prospective controlled study with 10 years of follow-up. Objective To determine the attributable risk of community acquired pneumonia on incidence of heart failure throughout the age range of affected patients and severity of the infection. Design Cohort study. Setting Six hospitals and seven emergency departments in Edmonton, Alberta, Canada, 2000-02. Participants 4988 adults with community acquired pneumonia and no history of heart failure (...) were prospectively recruited and matched on age, sex, and setting of treatment (inpatient or outpatient) with up to five adults without pneumonia (controls) or prevalent heart failure (n=23 060). Main outcome measures Risk of hospital admission for incident heart failure or a combined endpoint of heart failure or death up to 2012, evaluated using multivariable Cox proportional hazards analyses. Results The average age of participants was 55 years, 2649 (53.1%) were men, and 63.4% were managed

BMJ2017

179. Association between matrix metalloproteinase‐9 and worsening heart failure events in patients with chronic heart failure

Association between matrix metalloproteinase‐9 and worsening heart failure events in patients with chronic heart failure 28772055 2018 11 13 2055-5822 4 3 2017 Aug ESC heart failure ESC Heart Fail Association between matrix metalloproteinase-9 and worsening heart failure events in patients with chronic heart failure. 321-330 10.1002/ehf2.12137 Matrix metalloproteinase (MMP) is up-regulated during heart failure (HF) and influences ventricular remodeling. We hypothesized that disparity between (...) MMP-9 and tissue inhibitors of MMP-1 (TIMP-1) results in clinical manifestations and is related to prognostic risk in patients with chronic HF. Plasma levels of MMP-9, TIMP-1, and brain natriuretic peptide (BNP) were measured in 173 patients with chronic HF. Combined endpoints of worsening HF events were assessed during follow-up (median 109 months). MMP-9 and TIMP-1 levels and the MMP-9/TIMP-1 ratio increased with increasing severity of the New York Heart Association class (P for trend = 0.003

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

180. Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure.

Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure. BACKGROUND: Mechanical circulatory support with a left ventricular assist device (LVAD) is an established treatment for patients with advanced heart failure. We compared a newer LVAD design (a small intrapericardial centrifugal-flow device) against existing technology (a commercially available axial-flow device) in patients with advanced heart failure who were ineligible for heart transplantation. METHODS: We conducted (...) , 12.56 percentage points; P=0.01 for noninferiority). More patients in the control group than in the study group had device malfunction or device failure requiring replacement (16.2% vs. 8.8%), and more patients in the study group had strokes (29.7% vs. 12.1%). Quality of life and functional capacity improved to a similar degree in the two groups. CONCLUSIONS: In this trial involving patients with advanced heart failure who were ineligible for heart transplantation, a small, intrapericardial

NEJM2017